S&P Futures
4,247.00+1.25(+0.03%)Dow Futures
34,460.00-2.00(-0.01%)Nasdaq Futures
14,015.00+20.75(+0.15%)
bluebird bio, Inc. (BLUE)
Chart Events
Performance Outlook
| Previous Close | 33.89 |
| Open | 34.25 |
| Bid | 33.80 x 1000 |
| Ask | 33.95 x 1000 |
| Day's Range | 33.30 - 34.37 |
| 52 Week Range | 24.24 - 68.39 |
| Volume | 1,249,046 |
| Avg. Volume | 1,357,782 |
| Market Cap | 2.3B |
| Beta (5Y Monthly) | 1.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -9.95 |
| Earnings Date | Aug 03, 2021 - Aug 09, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 48.86 |
- Business Wire
BLUEBIRD BIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE
NEW ORLEANS, Jun 12, 2021--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into bluebird bio, Inc. (NasdaqGS: BLUE).
- Business Wire
betibeglogene autotemcel (beti-cel) One-Time Gene Therapy for β-thalassemia Continues to Demonstrate Durable Efficacy Across Pediatric and Adult Patient Populations and All Genotypes in Data Presented at EHA2021 Virtual
CAMBRIDGE, Mass., Jun 11, 2021--bluebird bio, Inc. (Nasdaq: BLUE) today presented data from several studies of betibeglogene autotemcel (beti-cel) gene therapy (licensed as ZYNTEGLO™ in the EU and UK) in adult, adolescent and pediatric patients with transfusion-dependent β-thalassemia (TDT). These data were presented during EHA2021 Virtual, the 26th Annual Congress of the European Hematology Association, taking place June 9-17, 2021.
- Motley Fool
Bluebird bio Can Restart Halted Clinical Trials
The FDA has lifted the hold on bluebird bio's gene-therapy studies in sickle cell disease and transfusion-dependent β-thalassemia.
